IP Library Granted Patent US 8,426,585
Granted Patent B2
US 8,426,585 · App. 13/587,936 · Granted Apr 23, 2013

Compounds comprising a spiro-ring

Inventor: Ning Xi (Newbury Park, CA)
Assignees: Ning Xi; Sunshine Lake Pharma Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,426,585
App. No.
13/587,936
Granted
Apr 23, 2013
Kind
B2
Abstract

The present invention provides novel compounds useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Claims (70)

1. A compound of Formula (I):

or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof, wherein:

Q 1 is formula (IIa):

Q 2 is formula (III):

R 1 is hydroxy-substituted cyclopropylalkoxy, R 5 S(═O) 2 O-substituted cyclopropylalkoxy, spiro bicyclyl, spiro heterobicyclyl, spiro bicyclyl aliphatic, spiro heterobicyclyl aliphatic, spiro bicycloxy, spiro heterobicyclylamino, spiro bicycloxoalkoxy, spiro heterobicycloxoalkoxy, spiro bicyclylaminoalkoxy, spiro heterobicyclylaminoalkoxy, spiro bicyclyl —C(═O)—, spiro bicyclyl-C(═O)O—, spiro heterobicyclyl-C(═O)—, spiro heterobicyclyl-C(═O)O—, spiro bicyclylamino-C(═O)—, spiro heterobicyclylamino-C(═O)—, spiro bicyclyl-C(═O)NR 5 —, or spiro heterobicyclyl-C(═O)NR 5 —, or R 1 has one of the following structures:

wherein each of X 4 and X 4 ′ is independently (CR 4 R 4a ) m , NR 5 , O, S, S═O or SO 2 ; each of m and n is independently 0, 1 or 2; and t is 1, 2 or 3;

R 2 is H, halo, cyano, hydroxyl, R 5a R 5 N—, —C(═O)NR 5 R 5a , —OC(═O)NR 5 R 5a , —OC(═O)OR 5 , —NR 5 C(═O)NR 5 R 5a , —NR 5 C(═O)OR 5a , —NR 5 C(═O)—R 5a , R 5 R 5a N—O 2 S—, R 5 O 2 S—, R 5 O 2 SR 5a N—, R 5a R 5 N-alkyl, R 5 (S═O)-alkyl, R 5 R 5a N-(C═O)alkyl, R 5a R 5 N-alkoxy, R 5 (S═O)-alkoxy, R 5 R 5a N-(C═O)-alkoxy, aliphatic, alkoxy, hydroxyalkoxy, aminoalkoxy, hydroxy-substituted aminoalkoxy, haloalkoxy, amino-substituted haloalkoxy, alkylamino haloalkoxy, hydroxy-substituted haloalkoxy, alkylaminoalkoxy, alkoxyalkoxy, arylalkoxy, heterocyclylalkoxy, carbocyclylalkoxy, heterocyclyl(hydroxyalkoxy), carbocyclyl(hydroxyalkoxy), aryl(hydroxyalkoxy), aryloxyalkoxy, aryloxy, heterocyclyloxyalkoxy, carbocyclyloxyalkoxy, heterocyclyloxy, cycloalkyloxy, (heterocyclo)hydroxyalkoxy, azidoalkoxy, fused bicyclyl, fused heterobicyclyl, fused bicyclyl aliphatic, fused heterobicyclyl aliphatic, fused bicycloxy, fused heterobicycloxy, fused bicyclylamino, fused heterobicyclylamino, fused bicycloxoalkoxy, fused heterobicycloxoalkoxy, fused bicyclyl aminoalkoxy, fused heterobicyclyl aminoalkoxy, fused bicyclyl-C(═O)—, fused bicyclyl-C(═O)O—, fused heterobicyclyl-C(═O)—, fused heterobicyclyl-C(═O)O—, fused bicyclylamino-C(═O)—, fused heterobicyclylamino-C(═O)—, fused bicyclyl-C(═O)NR 5 —, fused heterobicyclyl-C(═O)NR 5 —, spiro bicyclyl, spiro heterobicyclyl, spiro bicyclyl aliphatic, spiro heterobicyclyl aliphatic, spiro bicycloxy, spiro heterobicycloxy, spiro bicyclylamino, spiro heterobicyclylamino, spiro bicycloxoalkoxy, spiro heterobicycloxoalkoxy, spiro bicyclylaminoalkoxy, spiro heterobicyclylaminoalkoxy, spiro bicyclyl —C(═O)—, spiro bicyclyl-C(═O)O—, spiro heterobicyclyl-C(═O)—, spiro heterobicyclyl-C(═O)O—, spiro bicyclylamino-C(═O)—, spiro heterobicyclylamino-C(═O)—, spiro bicyclyl-C(═O)NR 5 —, or spiro heterobicyclyl-C(═O)NR 5 —, aryl, heteroaryl, arylaliphatic or heteroarylaliphatic, with the proviso that when alkoxy or alkylamino is substituted, each of alkoxy or alkylamino is independently substituted with one or more hydroxy groups, amino groups or substituted amino groups;

R 3 is H, F, Cl, Br, I, —CN, hydroxyl, R 5a R 5 N—, aliphatic, alkoxy, haloalkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, cycloalkyl aliphatic, cycloalkylalkoxy, or heterocyclylalkoxy;

each of U 1 and U 2 is independently CR 4 or N;

V 1 is O or NR 5 ;

V 2 is cR 4 R 4a , NRS, CR 4 or N, and V 3 and V 4 combine to become CR 4 R 4a , NR 5 , O, CR 4 or N;

each of W 1 , W 2 , W 3 and W 4 is independently CR 4 R 4a , NR 5 , CR 4 or N;

X 1 is (CR 4 R 4a ) m , NR 5 , O, S, S═O or SO 2 , where m is 0, 1 or 2;

X 2 is O, S or NR 5 ;

Z is —NR 5 C(═O)—(CR 4 R 4a ) p —, —NR 5 C(═S)—(CR 4 R 4a ) p —, —NR 5a —(CR 4 R 4a ) p —, —NR 5 —(CR 4 R 4a ) p C(═O)—, —NR 5 —(CR 4 R 4a ) p C(═S)—, —NR 5 S(═O) r —, —NR 5 S(═O) r (CR 4 R 4a ) p —, —C(═O)NR 5 (CR 4 R 4a ) p — or —NR 5 —(CR 4 R 4a ) n S(═O) r —, where p is 0, 1, 2 or 3 and r is 1 or 2;

each of R 4 and R 4a is independently H, F, Cl, Br, I, —CN, hydroxyl, —NR 5a R 5 , alkoxy, cycloalkoxy, heterocycloalkoxy, aliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, arylaliphatic, heterocyclylaliphatic, cycloalkylaliphatic, aryloxyaliphatic, heterocyclyloxyaliphatic, cycloalkyloxyaliphatic, arylaminoaliphatic, heterocyclylaminoaliphatic, cycloalkylaminoaliphatic, aryl, heteroaryl, heterocyclyl or carbocyclyl, with the proviso that where R 4 and R 4a are bonded to the same carbon atom, R 4 and R 4a , together with the carbon atom they are attached to, optionally form a substituted or unsubstituted 3-8 membered carbocyclic or heterocyclic ring;

each of R 5 and R 5a is independently H, R 6 R 6a NC(═O)—, R 6 OC(═O)—, R 6 C(═O)—, R 6 R 6a NS(═O)—, R 6 OS(═O)—, R 6 S(═O)—, R 6 R 6a NSO 2 —, R 6 OSO 2 —, R 6 SO 2 —, aliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, arylaliphatic, heterocyclylaliphatic, cycloalkylaliphatic, aryloxyaliphatic, heterocyclyloxyaliphatic, cycloalkyloxyaliphatic, arylaminoaliphatic, heterocyclylaminoaliphatic, cycloalkylaminoaliphatic, aryl, heteroaryl, heterocyclyl or carbocyclyl, with the proviso that where R 5 and R 5a are bonded to the same nitrogen atom, R 5 and R 5a , together with the nitrogen atom they are attached to, optionally form a substituted or unsubstituted 3-8 membered ring, including spiro and fused bicyclic rings;

each of R 6 and R 6a is independently H, aliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, arylaliphatic, heterocyclylaliphatic, cycloalkylaliphatic, aryloxyaliphatic, heterocyclyloxyaliphatic, cycloalkyloxyaliphatic, arylaminoaliphatic, heterocyclylaminoaliphatic, cycloalkylaminoaliphatic, aryl, heteroaryl, heterocyclyl, or carbocyclyl;

wherein each of R 5a R 5 N—, —C(═O)NR 5 R 5a , —OC(═O)NR 5 R 5a , —OC(═O)OR 5 , —NR 5 C(═O)NR 5 R 5a , —NR 5 C(═O)OR 5a , —NR 5 C(═O)—R 5a , R 5 R 5 N—O 2 S—, R 5 O 2 S—, R 5 O 2 SR 5a N—, OR 5 , NR 5 , CR 4 R 4a , CR 4 , (CR 4 R 4a ) m , —NR 5 C(═O)—(CR 4 R 4a ) p —, —NR 5 C(═S)—(CR 4 R 4a ) p —, —NR 5a -(CR 4 R 4a ) p —, —NR 5 —(CR 4 R 4a ) p C(═O)—, —NR 5 —(CR 4 R 4a ) p C(═S)—, —NR 5 S(═O) r —, —NR 5 S(═O)(CR 4 R 4a ) p —, —C(═O)NR 5 —(CR 4 R 4a ) p —, —NR 5 —(CR 4 R 4a ) p —S(═O) r —, R 5a R 5 N-alkyl, R 5 S(═O)-alkyl, R 5 R 5 N—C(═O)-alkyl, R 5a R 5 N-alkoxy, R 5 S(═O), alkoxy, R 5 R 5 N—C(═O)-alkoxy, R 6 R 6a NC(═O)—, R 6 OC(═O)—, R 6 C(═O)—, R 6 R 6a NS(═O)—, R 6 OS(═O)—, R 6 S(═O)—, R 6 R 6a NSO 2 —, R 6 OSO 2 —, R 6 SO 2 —, hydroxy-substituted cyclopropylalkoxy, R 5 S(═O) 2 O-substituted cyclopropylalkoxy, aliphatic, alkoxy, hydroxyalkoxy, aminoalkoxy, hydroxy-substituted aminoalkoxy, haloalkoxy, amino-substituted haloalkoxy, alkylamino haloalkoxy, hydroxy-substituted haloalkoxy, alkylaminoalkoxy, alkoxyalkoxy, arylalkoxy, heterocyclylalkoxy, carbocyclylalkoxy, heterocyclyl(hydroxyalkoxy), carbocyclyl(hydroxyalkoxy), aryl(hydroxyalkoxy), aryloxyalkoxy, aryloxy, heterocyclyloxyalkoxy, carbocyclyloxyalkoxy, heterocyclyloxy, cycloalkyloxy, (heterocyclo)hydroxyalkoxy, azidoalkoxy, fused bicyclyl, fused heterobicyclyl, fused bicyclyl aliphatic, fused heterobicyclyl aliphatic, fused bicycloxy, fused heterobicycloxy, fused bicyclylamino, fused heterobicyclylamino, fused bicycloxoalkoxy, fused heterobicycloxoalkoxy, fused bicyclyl aminoalkoxy, fused heterobicyclyl aminoalkoxy, fused bicyclyl-C(═O)—, fused bicyclyl-C(═O)O—, fused heterobicyclyl-C(═O)—, fused heterobicyclyl-C(═O)O—, fused bicyclylamino-C(═O)—, fused heterobicyclylamino-C(═O)—, fused bicyclyl-C(═O)NR 5 —, fused heterobicyclyl-C(═O)NR 5 —, spiro bicyclyl, spiro heterobicyclyl, spiro bicyclyl aliphatic, spiro heterobicyclyl aliphatic, spiro bicycloxy, spiro heterobicycloxy, spiro bicyclylamino, spiro heterobicyclylamino, spiro bicycloxoalkoxy, spiro heterobicycloxoalkoxy, spiro bicyclylaminoalkoxy, spiro heterobicyclylaminoalkoxy, spiro bicyclyl —C(═O)—, spiro bicyclyl-C(═O)O—, spiro heterobicyclyl-C(═O)—, spiro heterobicyclyl-C(═O)O—, spiro bicyclylamino-C(═O)—, spiro heterobicyclylamino-C(═O)—, spiro bicyclyl-C(═O)NR 5 —, or spiro heterobicyclyl-C(═O)NR 5 —, aryl, heteroaryl, arylaliphatic and heteroarylaliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, aryloxyaliphatic, heterocyclyloxyaliphatic, cycloalkyloxyaliphatic, arylaminoaliphatic, heterocyclylaminoaliphatic, cycloalkylaminoaliphatic, arylaliphatic, heterocyclylaliphatic, cycloalkylaliphatic, heterocyclyl and carbocyclyl is independently substituted or unsubstituted.

2. The compound according to claim 1 , wherein R 3 is independently H, F, Cl, Br, —CN, C 1-3 aliphatic, C 1-3 alkoxy, or C 1-3 haloalkyl.

3. The compound according to claim 1 , wherein Q i is

wherein R 3a is H, F, Cl, Br, I, —CN, hydroxyl, R 5a R 5 N—, R 5a R 5 N-aliphatic, hydroxyaliphatic, aliphatic, alkoxy, alkoxyaliphatic, haloalkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, cycloalkoxy aliphatic, heterocycloxy aliphatic, cycloalkylalkoxy, heterocyclylalkoxy, aryloxyalkyl, heteroaryloxy aliphatic, arylaliphatic, heteroaryl aliphatic, aryl, or heteroaryl.

4. The compound according to claim 1 , wherein Q 2 is

5. The compound according to claim 1 , wherein X 1 is O or NR 5 .

6. The compound according to claim 1 , wherein Z of formula (IIa) is —NHC(═O)—, and the substructure defined by X 1 , U 1 and R 3 of Formula I is:

7. The compound according to claim 1 , wherein:

R 1 is hydroxy-substituted cyclopropyl C 1-6 alkoxy, R 5 S(═O) 2 O-substituted cyclopropyl C 1-6 alkoxy, C 5-12 spiro bicyclyl, C 5-12 spiro heterobicyclyl, C 5-12 spiro bicyclyl C 1-6 aliphatic, C 5-12 spiro heterobicyclyl C 1-6 aliphatic, C 5-12 spiro heterobicycloxo C 1-6 alkoxy, C 5-12 spiro heterobicyclylamino C 1-6 alkoxy, C 5-12 spiro bicyclyl —C(═O)—, C 5-12 spiro bicyclyl-C(═O)O—, C 5-12 spiro heterobicyclyl-C(═O)—, C 5-12 spiro heterobicyclyl-C(═O)O—, C 5-12 spiro bicyclylamino-C(═O)—, C 5-12 spiro heterobicyclylamino-C(═O)—, C 5-12 spiro bicyclyl-C(═O)NR 5 —, or C 5-12 spiro heterobicyclyl-C(═O)NR 5 —; and

R 2 is H, halo, cyano(CN), R 5a R 5 N—C 1-6 alkoxy, optionally substituted C 1-6 alkoxy, C 1-6 hydroxyalkoxy, C 1-6 aminoalkoxy, C 1-6 hydroxy-substituted aminoalkoxy, C 1-6 haloalkoxy, C 1-6 alkylamino C 1-6 alkoxy, C 1-6 alkoxy C 1-6 alkoxy, C 4-10 heterocyclyloxy C 1-6 alkoxy, C 5-12 fused bicyclyl, C 5-12 fused bicyclyl C 1-6 aliphatic, C 5-12 fused heterobicyclyl C 1-6 aliphatic, C 5-12 fused bicycloxy, C 5-12 fused bicyclylamino, C 5-12 fused bicycloxo C 1-6 alkoxy, C 5-12 fused bicyclylamino C 1-6 alkoxy, C 5-12 fused bicyclyl-C(═O)—, C 5-12 fused bicyclyl-C(═O)O—, C 5-12 fused heterobicyclyl-C(═O)—, C 5-12 fused heterobicyclyl-C(═O)O—, C 5-12 fused bicyclylamino-C(═O)—, C 5-12 fused heterobicyclylamino-C(═O)—, C 5-12 fused bicyclyl-C(═O)NR 5 —, C 5-12 fused heterobicyclyl-C(═O)NR 5 —, C 5-12 spiro bicyclyl, C 5-12 spiro bicycloxy, C 5-12 spiro bicyclylamino, C 5-12 spiro bicycloxo C 1-6 alkoxy, C 5-12 spiro bicyclylamino C 1-6 alkoxy, C 5-12 fused heterobicyclyl, C 5-12 fused heterobicycloxy, C 5-12 fused heterobicyclylamino, C 5-12 fused heterobicycloxo C 1-6 alkoxy, C 5-12 fused heterobicyclylamino C 1-6 alkoxy, C 5-12 spiro bicyclyl, C 5-12 spiro heterobicyclyl, C 5-12 spiro bicyclyl C 1-6 aliphatic, C 5-12 spiro heterobicyclyl C 1-6 aliphatic, C 5-12 spiro heterobicycloxo C 1-6 alkoxy, C 5-12 spiro heterobicyclylamino C 1-6 alkoxy, C 5-12 spiro bicyclyl —C(═O)—, C 5-12 spiro bicyclyl-C(═O)O—, C 5-12 spiro heterobicyclyl-C(═O)—, C 5-12 spiro heterobicyclyl-C(═O)O—, C 5-12 spiro bicyclylamino-C(═O)—, C 5-12 spiro heterobicyclylamino-C(═O)—, C 5-12 spiro bicyclyl-C(═O)NR 5 —, or C 5-12 spiro heterobicyclyl-C(═O)NR 5 —, C 6-10 aryl, C 1-10 heteroaryl, C 6-10 aryl C 1-6 aliphatic or C 1-10 heteroaryl C 1-6 aliphatic.

8. The compound according to claim 1 , wherein R 1 has one of the following structures:

wherein each of X 4 and X 4 ′ is independently (CR 4 R 4a ) m , Me, O, S, S═O or SO 2 ; each of m and n is independently 0, 1 or 2; and t is 1, 2 or 3.

9. The compound of claim 1 having one of the following structures:

or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof.

10. A compound of Formula (IV):

or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof, wherein:

Q 2 has formula (III):

R 1 is one of the following structures:

wherein each of X 4 and X 4 ′ is independently (CR 4 R 4a ) m , NR 5 , O, S, S═O or SO 2 ; each of m and n is independently 0, 1 or 2; and t is 1, 2 or 3;

R 2 is H, halo, cyano, hydroxyl, R 5a R 5 N—, —C(═O)NR 5 R 5a , —OC(═O)NR 5 R 5a , —OC(═O)OR 5 , —NR 5 C(═O)NR 5 R 5a , —NR 5 C(═O)OR 5a , —NR 5 C(═O)—R 5a , R 5 R 5a N—O 2 S—, R 5 O 2 S—, R 5 O 2 SR 5a N—, R 5a R 5 N-alkyl, R 5 S(═O)-alkyl, R 5 R 5a N-C(═O)-alkyl, R 5a R 5 N-alkoxy, R 5 S(═O)-alkoxy, R 5 R 5a N-C(═O)-alkoxy, aliphatic, alkoxy, hydroxyalkoxy, aminoalkoxy, hydroxy-substituted aminoalkoxy, haloalkoxy, amino-substituted haloalkoxy, alkylamino haloalkoxy, hydroxy-substituted haloalkoxy, alkylaminoalkoxy, alkoxyalkoxy, arylalkoxy, heterocyclylalkoxy, carbocyclylalkoxy, heterocyclyl(hydroxyalkoxy), carbocyclyl(hydroxyalkoxy), aryl(hydroxyalkoxy), aryloxyalkoxy, aryloxy, heterocyclyloxyalkoxy, carbocyclyloxyalkoxy, heterocyclyloxy, cycloalkyloxy, (heterocyclo)hydroxyalkoxy, azidoalkoxy, fused bicyclyl, fused heterobicyclyl, fused bicyclyl aliphatic, fused heterobicyclyl aliphatic, fused bicycloxy, fused heterobicycloxy, fused bicyclylamino, fused heterobicyclylamino, fused bicycloxoalkoxy, fused heterobicycloxoalkoxy, fused bicyclyl aminoalkoxy, fused heterobicyclyl aminoalkoxy, fused bicyclyl-C(═O)—, fused bicyclyl-C(═O)O—, fused heterobicyclyl-C(═O)—, fused heterobicyclyl-C(═O)O—, fused bicyclylamino-C(═O)—, fused heterobicyclylamino-C(═O)—, fused bicyclyl-C(═O)NR 5 —, fused heterobicyclyl-C(═O)NR 5 —, spiro bicyclyl, spiro heterobicyclyl, spiro bicyclyl aliphatic, spiro heterobicyclyl aliphatic, spiro bicycloxy, spiro heterobicycloxy, spiro bicyclylamino, spiro heterobicyclylamino, spiro bicycloxoalkoxy, spiro heterobicycloxoalkoxy, spiro bicyclylaminoalkoxy, spiro heterobicyclylaminoalkoxy, spiro bicyclyl —C(═O)—, spiro bicyclyl-C(═O)O—, spiro heterobicyclyl-C(═O)—, spiro heterobicyclyl-C(═O)O—, spiro bicyclylamino-C(═O)—, spiro heterobicyclylamino-C(═O)—, spiro bicyclyl-C(═O)NR 5 —, or spiro heterobicyclyl-C(═O)NR 5 —, aryl, heteroaryl, arylaliphatic or heteroarylaliphatic, with the proviso that when alkoxy or alkylamino is substituted, each of alkoxy or alkylamino is independently substituted with one or more hydroxy groups, amino groups or substituted amino groups;

R 3 is H, F, Cl, Br, I, —CN, hydroxyl, R 5a R 5 N—, aliphatic, alkoxy, haloalkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, cycloalkyl aliphatic, cycloalkylalkoxy, or heterocyclylalkoxy;

each of U 1 and U 2 is independently CR 4 or N;

V 1 is O or NR 5 ;

V 2 is cR 4 R 4a , NR 5 , CR 4 or N, and V 3 and V 4 combine to become CR 4 R 4a , NR 5 , O, CR 4 or N;

each of W 1 , W 2 , W 3 and W 4 is independently CR 4 R 4a , NR 5 , CR 4 or N;

X 1 is (CR 4 R 4a ) m , NR 5 , O, S, S═O or SO 2 , where m is 0, 1 or 2;

X 2 is independently O, S or NR 5 ;

Z is —NR 5 C(═O)—(CR 4 R 4a ) p —, —NR 5 C(═S)—(CR 4 R 4a ) p —, —NR 5a —(CR 4 R 4a ) p —, —NR 5 —(CR 4 R 4a ) p C(═O)—, —NR 5 —(CR 4 R 4a ) p C(═S)—, —NR 5 S(═O) r —, —NR 5 S(═O) r (CR 4 R 4a ) p —, —C(═O)NR 5 (CR 4 R 4a ) p — or —NR 5 (CR 4 R 4a ) p S(═O) r —, where p is 0, 1, 2 or 3; and r is 1 or 2;

each of R 4 and R 4a is independently H, F, Cl, Br, I, —CN, hydroxyl, —NR 5a R 5 , alkoxy, cycloalkoxy, heterocycloalkoxy, aliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, aryloxyaliphatic, heterocyclyloxyaliphatic, cycloalkyloxyaliphatic, arylaminoaliphatic, heterocyclylaminoaliphatic, cycloalkylaminoaliphatic, arylaliphatic, heterocyclylaliphatic, cycloalkylaliphatic, aryl, heteroaryl, heterocyclyl or carbocyclyl, with the proviso that where R 4 and R 4a are bonded to the same carbon atom, R 4 and R 4a , together with the carbon atom they are attached to, optionally form a substituted or unsubstituted 3-8 membered carbocyclic or heterocyclic ring;

each of R 5 and R 5a is independently H, R 6 R 6a NC(═O)—, R 6 OC(═O)—, R 6 C(═O)—, R 6 R 6a NS(═O)—, R 6 OS(═O)—, R 6 S(═O)—, R 6 R 6a NSO 2 —, R 6 OSO 2 —, R 6 SO 2 —, aliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, arylaliphatic, heterocyclylaliphatic, cycloalkylaliphatic, aryloxyaliphatic, heterocyclyloxyaliphatic, cycloalkyloxyaliphatic, arylaminoaliphatic, heterocyclylaminoaliphatic, cycloalkylaminoaliphatic, aryl, heteroaryl, heterocyclyl or carbocyclyl, with the proviso that where R 5 and R 5a are bonded to the same nitrogen atom, R 5 and R 5a , together with the nitrogen atom they are attached to, optionally form a substituted or unsubstituted 3-8 membered ring, including spiro and fused bicyclic rings;

each of R 6 and R 6a is independently H, aliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, arylaliphatic, heterocyclylaliphatic, cycloalkylaliphatic, aryloxyaliphatic, heterocyclyloxyaliphatic, cycloalkyloxyaliphatic, arylaminoaliphatic, heterocyclylaminoaliphatic, cycloalkylaminoaliphatic, aryl, heteroaryl, heterocyclyl, or carbocyclyl;

wherein each of R 5a R 5 N—, —C(═O)NR 5 R 5a , —OC(═O)NR 5 R 5a , —OC(═O)OR 5 , —NR 5 C(═O)NR 5 R 5a , —NR 5 C(═O)OR 5a , —NR 5 C(═O)—R 5a , R 5 R 5a N-O 2 S—, R 5 O 2 S—, R 5 O 2 SR 5a N—, OR 5 , NR 5 , CR 4 R 4a , CR 4 , (CR 4 R 4a ) m , —NR 5 C(═O)—(CR 4 R 4a ) p —, —NR 5 C(═S)—(CR 4 R 4a ) p —, —NR 5a -(CR 4 R 4a ) p —, —NR 5 —(CR 4 R 4a ) p C(═O)—, —NR 5 —(CR 4 R 4a ) p C(═S)—, —NR 5 S(═O) r —, —NR 5 S(═O)(CR 4 R 4a ) p —, —C(═O)NR 5 —(CR 4 R 4a ) p —, —NR 5 —(CR 4 R 4a ) p —S(═O) r —, R 5a R 5 N-alkyl, R 5 (S═O)-alkyl, R 5 R 5a N—(C═O)-alkyl, R 5a R 5 N-alkoxy, R 5 (S═O)-alkoxy, R 5 R 5 N—(C═O)-alkoxy, R 6 R 6a NC(═O)—, R 6 OC(═O)—, R 6 C(═O)—, R 6 R 6a NS(═O)—, R 6 OS(═O)—, R 6 S(═O)—, R 6 R 6a NSO 2 —, R 6 OSO 2 —, R 6 SO 2 —, hydroxy-substituted cyclopropylalkoxy, R 5 S(═O) 2 O-substituted cyclopropylalkoxy, aliphatic, alkoxy, hydroxyalkoxy, aminoalkoxy, hydroxy-substituted aminoalkoxy, haloalkoxy, amino-substituted haloalkoxy, alkylamino haloalkoxy, hydroxy-substituted haloalkoxy, alkylaminoalkoxy, alkoxyalkoxy, arylalkoxy, heterocyclylalkoxy, carbocyclylalkoxy, heterocyclyl(hydroxyalkoxy), carbocyclyl(hydroxyalkoxy), aryl(hydroxyalkoxy), aryloxyalkoxy, aryloxy, heterocyclyloxyalkoxy, carbocyclyloxyalkoxy, heterocyclyloxy, cycloalkyloxy, (heterocyclo)hydroxyalkoxy, azidoalkoxy, fused bicyclyl, fused heterobicyclyl, fused bicyclyl aliphatic, fused heterobicyclyl aliphatic, fused bicycloxy, fused heterobicycloxy, fused bicyclylamino, fused heterobicyclylamino, fused bicycloxoalkoxy, fused heterobicycloxoalkoxy, fused bicyclyl aminoalkoxy, fused heterobicyclyl aminoalkoxy, fused bicyclyl-C(═O)—, fused bicyclyl-C(═O)O—, fused heterobicyclyl-C(═O)—, fused heterobicyclyl-C(═O)O—, fused bicyclylamino-C(═O)—, fused heterobicyclylamino-C(═O)—, fused bicyclyl-C(═O)NR 5 —, fused heterobicyclyl-C(═O)NR 5 —, spiro bicyclyl, spiro heterobicyclyl, spiro bicyclyl aliphatic, spiro heterobicyclyl aliphatic, spiro bicycloxy, spiro heterobicycloxy, spiro bicyclylamino, spiro heterobicyclylamino, spiro bicycloxoalkoxy, spiro heterobicycloxoalkoxy, spiro bicyclylaminoalkoxy, spiro heterobicyclylaminoalkoxy, spiro bicyclyl —C(═O)—, spiro bicyclyl-C(═O)O—, spiro heterobicyclyl-C(═O)—, spiro heterobicyclyl-C(═O)O—, spiro bicyclylamino-C(═O)—, spiro heterobicyclylamino-C(═O)—, spiro bicyclyl-C(═O)NR 5 —, or spiro heterobicyclyl-C(═O)NR 5 —, aryl, heteroaryl, arylaliphatic and heteroarylaliphatic, haloaliphatic, hydroxyaliphatic, aminoaliphatic, alkoxyaliphatic, alkylaminoaliphatic, alkylthioaliphatic, aryloxyaliphatic, heterocyclyloxyaliphatic, cycloalkyloxyaliphatic, arylaminoaliphatic, heterocyclylaminoaliphatic, cycloalkylaminoaliphatic, arylaliphatic, heterocyclylaliphatic, cycloalkylaliphatic, heterocyclyl and carbocyclyl is independently substituted or unsubstituted.

11. The compound according to claim 10 , wherein R 3 is independently H, F, Cl, Br, —CN, C 1-3 aliphatic, C 1-3 alkoxy, or C 1-3 haloalkyl.

12. The compound according to claim 10 , wherein the substructure defined by X 2 , V 1 , V 2 , V 3 , V 4 and Z of Formula (IV) is

wherein R 3a is H, F, Cl, Br, I, —CN, hydroxyl, R 5a R 5 N—, R 5a R 5 N-aliphatic, hydroxyaliphatic, aliphatic, alkoxy, alkoxyaliphatic, haloalkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl, cycloalkoxy aliphatic, heterocycloxy aliphatic, cycloalkylalkoxy, heterocyclylalkoxy, aryloxyalkyl, heteroaryloxy aliphatic, arylaliphatic, heteroaryl aliphatic, aryl, or heteroaryl.

13. The compound according to claim 10 wherein Q 2 is

14. The compound according to claim 10 , wherein X 1 is O or NR 5 .

15. The compound according to claim 10 , wherein Z is —NHC(═O)—.

16. The compound according to claim 10 , wherein the substructure defined by X i , Z, U 1 and R 3 is

17. The compound according to claim 1 , wherein the substructure defined by X 1 , Z, U 1 and R 3 of Formula (IV) is:

the substructure defined by X 2 , V 1 , V 2 , V 3 , V 4 and Z of Formula (IV) is:

Q 2 is

R 1 is

wherein each of X 4 and X 4 ′ is independently O, and t is 3;

R 2 is H;

R 3a is aliphatic; and

each of R 5 and R 5a is independently H, aliphatic or aryl.

18. The compound of claim 10 having one of the following structures:

or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof.

20. The composition according to claim 19 further comprising a therapeutic agent selected from a chemotherapeutic agent, an anti-proliferative agent, an agent for treating atherosclerosis, an agent for treating lung fibrosis, and combinations thereof.

21. The composition according to claim 20 , wherein the additional therapeutic agent is adriamycin, rapamycin, temsirolimus, everolimus, ixabepilone, gemcitabin, cyclophosphamide, dexamethasone, etoposide, fluorouracil, imatinib mesylate, dasatinib, nilotinib, erlotinib, lapatinib, iressa, sorafenib, sunitinib, an interferon, carboplatin, topotecan, taxol, vinblastine, vincristine, temozolomide, tositumomab, trabecdectin, bevacizumab, panitumumab, or a combination thereof.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 4, 2021
From: CALITOR SCIENCES, LLC.
To: SUNSHINE LAKE PHARMA CO., LTD.
Reel/Frame 056177/0572 →
CORRECTIVE ASSIGNMENT TO CORRECT THE 15/961,688 PREVIOUSLY RECORDED ON REEL 052922 FRAME 0077. ASSIGNOR(S) HEREBY CONFIRMS THE THE ASSIGNMENT. Recorded Sep 29, 2020
From: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED; CALITOR SCIENCES, LLC
To: SUNSHINE LAKE PHARMA CO., LTD.; CALITOR SCIENCES LLC
Reel/Frame 053921/0538 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2020
From: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED; CALITOR SCIENCES, LLC
To: SUNSHINE LAKE PHARMA CO., LTD.; CALITOR SCIENCES LLC
Reel/Frame 052922/0077 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2019
From: XI, NING; SUNSHINE LAKE PHARMA CO., LTD.
To: NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED; CALITOR SCIENCES, LLC
Reel/Frame 050781/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2012
From: XI, NING
To: SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO., LTD.; XI, NING
Reel/Frame 028816/0393 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2012
From: XI, NING; SHENZHEN DONGYANGGUANG INDUSTRIAL DEVELOPMENT CO., LTD.
To: SUNSHINE LAKE PHARMA CO., LTD.; XI, NING
Reel/Frame 028816/0620 →
Continuity (3)
Division 12576375 · Oct 9, 2009
Provisional Application 61105414 · Oct 14, 2008
Related Publication 20120315247A1 · Dec 13, 2012